Addex Therapeutics : Addex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for Parkinson's Research

 Addex Therapeutics : Addex Therapeutics Awarded $1 MM Grant from The Michael
                  J. Fox Foundation for Parkinson's Research

Addex Therapeutics / Addex Therapeutics Awarded $1 MM Grant from The Michael
J. Fox Foundation for Parkinson's Research . Processed and transmitted by
Thomson Reuters ONE. The issuer is solely responsible for the content of this
announcement.

Grant to be used to help fund further human clinical testing of dipraglurant
for the treatment of Parkinson's disease levodopa-induced dyskinesia

New York, NY and Geneva, Switzerland, 19 March 2013 - Addex Therapeutics (SIX:
ADXN), a leading company pioneering allosteric modulation-based drug discovery
and development, and The  Michael J. Fox  Foundation for Parkinson's  Research 
announced today that  the Foundation awarded  a $1,000,000 grant  to Addex  to 
help fund continued human clinical  testing of dipraglurant for the  treatment 
of Parkinson's  disease  levodopa-induced dyskinesia  (PD-LID).  One-third  of 
people with  PD develop  dyskinesia  within four  to  six years  of  beginning 
levodopa treatment; this increases to  approximately 90 percent after nine  or 
more years. Patients with Parkinson's disease (PD) can live 10-20 years  after 
diagnosis; however, PD-LID is  a leading cause of  disability in this  growing 
patient population.

"Dyskinesia is a top  priority for our Foundation  because of its  significant 
negative impact on patients' quality of life," said Todd Sherer, Ph.D.,  Chief 
Executive Officer  of  The Michael  J.  Fox Foundation.  "Candidates  such  as 
dipraglurant  and  other  innovative   therapies  in  development  offer   the 
possibility of improved quality of  life through better symptomatic  treatment 
of Parkinson's. Dipraglurant targets a molecular mechanism that our Foundation
has been  investing in  since 2005  and we  are pleased  to take  part in  its 
continued progress to the clinic. We are enthusiastic about funding this  work 
and hopeful that it may offer  patients relief from a longstanding issue  with 
the treatment of their disease."

Dyskinesias are the uncontrollable and disruptive movements that are caused by
long-term use of levodopa  (Sinemet), a dopamine  replacement therapy and  the 
gold-standard treatment  for Parkinson's  disease.  There is  no  FDA-approved 
treatment  for  dyskinesia.  Existing   treatment  options  are  limited   and 
insufficient to address  patients' medical  needs. Patients are  faced with  a 
lose-lose situation: Take as much levodopa  as needed to manage symptoms,  and 
cope with dyskinesia; or take less medicine  in an effort to delay or  prevent 
dyskinesia, and cope with symptoms. The Michael J. Fox Foundation has invested
more than  $26  million in  dyskinesia-targeted  research to  date,  including 
support for a successful Phase 2a trial of dipraglurant completed by Addex  in 
2012.

"We are  extremely pleased  to receive  this  grant from  The Michael  J.  Fox 
Foundation supporting the further  development of dipraglurant," said  Bharatt 
Chowrira, Ph.D., Chief  Executive Officer of  Addex Therapeutics. "We  believe 
the successful  completion of  the Phase  2a study  offers some  promise  that 
dipraglurant has the potential to  significantly change both the way  patients 
are treated as well  as their quality of  life. The work we  will be able  to 
pursue with  this grant  is  critical to  our  continued advancement  of  this 
important approach to  the treatment  of PD-LID.  Ultimately, we  hope to  see 
dipraglurant become the first drug to alleviate all PD-LID symptoms."

Dipraglurant is an  oral, small  molecule allosteric  modulator that  inhibits 
selectively  the  metabotropic  glutamate  receptor  5  (mGluR5),  a  Class  C 
G-Protein Coupled Receptor (GPCR). Dipraglurant holds potential to be used  in 
combination with levodopa or dopamine  agonists, or as a standalone  treatment 
for PD-LID, PD-related motor symptoms, dystonia, non-motor symptoms of PD  and 
other movement disorders. Data  from a Phase 2a  showed that dipraglurant  met 
the  primary  objective  of  the  study  by  exhibiting  a  good  safety   and 
tolerability  profile.   Dipraglurant   also  demonstrated   a   statistically 
significant reduction  in  LID  severity  with  both  50  and  100  mg  doses. 
Dipraglurant appears to reduce  dystonia severity in  addition to chorea,  the 
two  major  LID  components.  In  a  double-blind,  placebo-controlled   study 
conducted in  the US  and Europe,  the primary  objective was  to  demonstrate 
safety and  tolerability  in  PD-LID  patients. In  addition,  the  trial  was 
designed to evaluate exploratory efficacy  as a secondary objective.  Efficacy 
was measured using the modified  Abnormal Involuntary Movement Scale  (mAIMS), 
patient  diaries   documenting  "off-time"   (impaired  voluntary   movement), 
"on-time" (with or without dyskinesia) and sleep. The trial was supported by a
grant from The Michael J. Fox Foundation for Parkinson's Research.

About The Michael J. Fox Foundation for Parkinson's Research

As the world's largest private funder of Parkinson's research, The Michael  J. 
Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and
improved therapies for those living  with the condition today. The  Foundation 
pursues its goals  through an  aggressively funded,  highly targeted  research 
program coupled  with  active  global engagement  of  scientists,  Parkinson's 
patients,  business   leaders,  clinical   trial  participants,   donors   and 
volunteers. In addition  to funding  more than  $300 million  in research  to 
date, the  Foundation has  fundamentally altered  the trajectory  of  progress 
toward a cure.  Operating at the  hub of worldwide  Parkinson's research,  the 
Foundation  forges  groundbreaking   collaborations  with  industry   leaders, 
academic scientists and  government research  funders; increases  the flow  of 
participants into Parkinson's  disease clinical trials  with its online  tool, 
Fox  Trial  Finder;  promotes   Parkinson's  awareness  through   high-profile 
advocacy, events and outreach; and  coordinates the grassroots involvement  of 
thousands of Team Fox members around the world.

For more information, visit us at:
Web site: michaeljfox.org
Facebook: facebook.com/michaeljfoxfoundation
LinkedIn: bit.ly/mjffPDOR
Twitter: @MichaelJFoxOrg

About Addex Therapeutics
Addex Therapeutics (www.addextherapeutics.com) is a development stage  company 
focused on advancing  innovative oral  small molecules  against rare  diseases 
utilizing its pioneering allosteric modulation-based drug discovery  platform. 
The Company's two  lead products are  being investigated in  Phase 2  clinical 
testing: dipraglurant (dipraglurant, an mGlu5 negative allosteric modulator or
NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced
dyskinesia (PD-LID) and rare forms  of dystonia; and ADX71149 (mGlu2  positive 
allosteric modulator or PAM) is being developed in collaboration with  Janssen 
Pharmaceuticals, Inc.  to treat  both  schizophrenia and  anxiety as  seen  in 
patients suffering from  major depressive  disorder. Addex  is also  advancing 
several preclinical programs including: GABA-BR positive allosteric  modulator 
(PAM) for Charcot-Marie-Tooth (type 1a)  disease, spasticity in patients  with 
multiple sclerosis (MS),  pain, overactive  bladder and  other disorders;  and 
mGlu4 PAM for MS, Parkinson's disease, anxiety and other diseases.  Allosteric 
modulators are  an emerging  class  of small  molecule  drugs which  have  the 
potential to be  more specific and  confer significant therapeutic  advantages 
over conventional  "orthosteric"  small  molecule  or  biological  drugs.  The 
Company uses its proprietary discovery platform to target receptors and  other 
proteins that are recognized  as essential for  the therapeutic modulation  of 
important diseases with unmet medical needs.

Tim Dyer
Chief Financial Officer
Addex Therapeutics
+41 22 884 15 61
PR@addextherapeutics.com

Disclaimer: The foregoing release may contain forward-looking statements  that 
can be  identified  by  terminology  such  as  "not  approvable",  "continue", 
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by  express or implied discussions regarding  Addex 
Therapeutics, formerly  known as,  Addex  Pharmaceuticals, its  business,  the 
potential approval of  its products  by regulatory  authorities, or  regarding 
potential future revenues from such products. Such forward-looking  statements 
reflect the  current  views of  Addex  Therapeutics regarding  future  events, 
future economic performance or prospects,  and, by their very nature,  involve 
inherent risks and uncertainties, both general and specific, whether known  or 
unknown, and/or any other  factor that may materially  differ from the  plans, 
objectives, expectations,  estimates and  intentions expressed  or implied  in 
such forward-looking statements. Such may  in particular cause actual  results 
with  allosteric  modulators  of  mGlu2,   mGlu4,  mGlu5,  GABA-BR  or   other 
therapeutic targets  to  be  materially different  from  any  future  results, 
performance or achievements expressed or implied by such statements. There can
be no guarantee that allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR  or 
other therapeutics targets will be approved for  sale in any market or by  any 
regulatory  authority.  Nor  can  there  be  any  guarantee  that   allosteric 
modulators of mGlu2, mGlu4, mGlu5,  GABA-BR or other therapeutic targets  will 
achieve  any  particular  levels  of  revenue  (if  any)  in  the  future.  In 
particular,  management's  expectations  regarding  allosteric  modulators  of 
mGlu2, mGlu4, mGlu5, GABA-BR  or other therapeutic  targets could be  affected 
by, among  other  things,  unexpected  actions  by  our  partners,  unexpected 
regulatory actions or  delays or government  regulation generally;  unexpected 
clinical trial results, including unexpected new clinical data and  unexpected 
additional  analysis  of  existing  clinical  data;  competition  in  general; 
government, industry  and  general  public pricing  pressures;  the  company's 
ability to  obtain  or  maintain  patent  or  other  proprietary  intellectual 
property protection.  Should  one or  more  of these  risks  or  uncertainties 
materialize, or should underlying assumptions prove incorrect, actual  results 
may vary materially from those  anticipated, believed, estimated or  expected. 
Addex Therapeutics is providing  the information in this  press release as  of 
this date and does not undertake any obligation to update any  forward-looking 
statements contained in  this press release  as a result  of new  information, 
future events or otherwise, except as may be required by applicable laws.

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Addex Therapeutics via Thomson Reuters ONE
HUG#1686216

--- End of Message ---

Addex Therapeutics
12, chemin des Aulx Plan-les-Ouates; Geneva Switzerland

ISIN: CH0029850754;